# US Glioblastoma Multiforme Market > US Glioblastoma Multiforme Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field (TTF) Therapy, Others) and By End Users (Hospitals & Clinics, Ambulatory Surgical Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.52% - **2024:** $ 617.6 Million - **2025:** $ 670.22 Million - **2035:** $ 1,518.46 Million - **Key Players:** Bristol-Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE) **Report ID:** MRFR/HC/12173-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-glioblastoma-multiforme-market-13698 --- ## Market Summary ## **US Glioblastoma Multiforme Market Overview** As per MRFR analysis, the US Glioblastoma Multiforme Market Size was estimated at 406.38 (USD Million) in 2023. The US Glioblastoma Multiforme Market Industry is expected to grow from 441(USD Million) in 2024 to 1,084 (USD Million) by 2035. The US Glioblastoma Multiforme Market CAGR (growth rate) is expected to be around 8.52% during the forecast period (2025 - 2035). ### **Key US Glioblastoma Multiforme Market Trends Highlighted** The US Glioblastoma Multiforme market is witnessing significant trends driven predominantly by advancements in treatment modalities and increasing research efforts. One key market driver is the growing emphasis on personalized medicine, where therapies are tailored to the genetic makeup of patients. This approach is supported by various research initiatives funded by government bodies like the National Institutes of Health, which has made substantial investments in cancer research, particularly in glioblastoma, to improve treatment outcomes. Additionally, there is an upward trend in clinical trials, with many pharmaceutical companies seeking to discover and develop innovative therapies such as immunotherapy and targeted therapy. This focus on new treatment avenues is bolstered by collaborations between academic institutions and private sectors, aiming to expedite the transition of research into clinical practice. Opportunities in the US [Glioblastoma Multiforme](../../../reports/glioblastoma-multiforme-market-12161) market are abundant, particularly in the areas of drug development and innovative delivery methods. Biotech firms and start-ups are increasingly exploring novel compounds and drug combinations that could offer better efficacy and safety profiles for patients. Furthermore, the rising awareness about glioblastoma and advocacy from patient organizations is leading to increased funding and support for research initiatives. Recent trends in the US also show a heightened interest in utilizing advanced technologies like artificial intelligence to analyze treatment responses and improve patient outcomes. Furthermore, telemedicine has become crucial in providing access to care, enhancing patient monitoring, and facilitating clinical trial participation, especially in rural areas. In summary, the US Glioblastoma Multiforme market continues to experience robust developments due to a combination of innovative treatment strategies, research funding, and technological advancements, all of which present new opportunities for growth and improved patient care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Glioblastoma Multiforme Market Drivers** ### **Increasing Incidence of Glioblastoma Multiforme** The United States has been witnessing a rise in the incidence of Glioblastoma Multiforme, with the Central Brain Tumor Registry of the United States reporting that approximately 3.19 cases per 100,000 individuals are diagnosed annually. This increased incidence is likely to drive the growth of the US Glioblastoma Multiforme Market Industry as the demand for effective treatment options rises. Major healthcare institutions such as the American Cancer Society and the National Cancer Institute are actively engaged in collecting and disseminating data regarding brain cancer incidences, helping to raise awareness and urging the need for innovative treatment solutions. These organizations not only play a crucial role in educating the public but also aim to enhance funding for Research and Development to support effective clinical practices. The growing pool of patients represents a significant market opportunity, indicating a strong upward trajectory for the market as awareness and funding lead to advancements in treatment technologies. ### **Advancements in Treatment Technologies** The US Glioblastoma Multiforme Market Industry is benefiting from rapid advancements in treatment methodologies, including innovations in surgical techniques, radiation therapy, and emerging drug therapies such as targeted therapies and immunotherapies. According to the National Institutes of Health, substantial resources have been allocated to the development of newer therapy options for Glioblastoma Multiforme, contributing to improved patient outcomes. The US Food and Drug Administration has also accelerated the approval process for novel therapeutics aimed at treating aggressive brain tumors, allowing for faster patient access to groundbreaking treatments. These technological advancements are likely to stimulate market growth, especially with organizations like the American Society of Clinical Oncology advocating for enhanced treatment options and providing guidelines that promote novel treatment pathways. ### **Increased Government and Non-profit Funding** Significant funding from both government and non-profit sectors aimed at combating Glioblastoma Multiforme is anticipated to fuel the growth of the US Glioblastoma Multiforme Market Industry. The National Cancer Institute has committed substantial resources towards glioblastoma research, earmarking around USD 150 million in recent budget allocations for brain tumor research initiatives. These funding measures are focused on supporting Research and Development, fostering partnerships with academic institutions and biotech companies to expedite clinical trials. Additionally, non-profit organizations such as the National Brain Tumor Society are instrumental in funding research initiatives, emphasizing innovative treatment strategies. Increased governmental and non-profit funding can lead to enhanced research efforts that facilitate breakthroughs in treatment options, bolstering market growth and providing hope to patients diagnosed with this challenging condition. ## **US Glioblastoma Multiforme Market Segment Insights** ### **Glioblastoma Multiforme Market Treatment Type Insights** The Treatment Type segment within the US Glioblastoma Multiforme Market encompasses various therapeutic approaches designed to combat this aggressive form of brain cancer. Surgery is often the initial step in treatment, focusing on the removal of as much tumor mass as possible, which is critical in extending patient survival and improving quality of life. Radiation therapy complements surgical efforts by targeting residual tumor cells, thereby reducing the chances of recurrence. Chemotherapy continues to be a cornerstone of treatment, employing agents that specifically aim to halt the growth and spread of cancerous cells, though it often carries side effects that impact patient compliance and quality of life. Emerging treatment modalities like immunotherapy are gaining prominence as they utilize the skin’s immune system to recognize and attack glioblastoma cells, which could potentially lead to better long-term outcomes. Additionally, Tumor Treating Field (TTF) Therapy represents an innovative approach, employing electric fields to disrupt cancer cell division, which serves as a crucial adjunct treatment particularly for patients who are not candidates for surgery. Other therapies, possibly including targeted therapies or novel agents, offer hope for personalized medicine strategies. The US Glioblastoma Multiforme Market is witnessing significant growth opportunities driven by research advancements, including ongoing clinical trials and collaborations between research institutions and pharmaceutical companies. Challenges remain, as the aggressive nature of glioblastoma often leads to treatment resistance, necessitating continuous exploration of new therapeutic avenues and improvement of existing ones. The market segment is characterized by a diverse offering in treatment options that cater to the varying needs of patients, while also aligning with the evolving landscape of cancer treatment in the US. Overall, the Treatment Type segment is pivotal in influencing patient management strategies and therapeutic outcomes within the broader US Glioblastoma Multiforme Market, reflecting a dynamic interplay of traditional and innovative approaches in the fight against this formidable disease. ## Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Glioblastoma Multiforme Market End User Insights** The US Glioblastoma Multiforme Market is influenced significantly by the End User segment, which comprises various healthcare facilities that provide treatment and care for patients. Hospitals and clinics constitute a major part of this segment and are considered essential for comprehensive care due to their capacity to offer advanced treatment options and specialized medical staff. This setting also plays a pivotal role in ongoing research, contributing valuable data towards innovative therapies for glioblastoma. Ambulatory surgical centers are becoming increasingly important in this landscape, providing outpatient procedures that allow patients to receive timely interventions with reduced hospital stays, which can enhance recovery times and lower healthcare costs. Furthermore, the 'Others' category encompasses various healthcare providers, such as specialty clinics that focus on neurology and oncology, contributing to the diverse treatment landscape. The demand for effective glioblastoma treatment within these settings is bolstered by rising incidence rates and advancements in medical technology, paving the way for improved patient care and outcomes across the US. ## **US Glioblastoma Multiforme Market Key Players and Competitive Insights** The US Glioblastoma Multiforme Market is characterized by a rapidly evolving landscape, driven by high unmet medical needs and advancements in therapeutic approaches. Competitive insights into this market reveal a strong presence of pharmaceutical companies that are consistently innovating to develop and bring to market new treatment options. The complexity of glioblastoma multiforme, a particularly aggressive brain tumor, necessitates a multifaceted approach to treatment, which ranges from traditional chemotherapy to cutting-edge immunotherapies and targeted therapies. Companies are continually working to enhance patient outcomes through clinical trials and collaborations, leading to shifts in market dynamics as new entrants emerge and established players enhance their portfolios. ### **Genentech** Genentech stands out within the US Glioblastoma Multiforme Market due to its commitment to research and development, particularly focusing on improving therapies for patients battling brain tumors. The company's strengths lie in its strong pipeline of innovative therapies and established reputation in oncology. Genentech has consistently leveraged its expertise in biotechnology to optimize treatment protocols for glioblastoma, creating a loyal customer base in the medical community and providing substantial support for patients. Their recent focus on combination therapies and personalized medicine further strengthens their position in the market, as they work to address the high resistance rates associated with traditional treatments. The company’s robust marketing strategies and patient engagement programs also enhance their market share by raising awareness of the significance of treatment options available. ### **Bristol Myers Squibb** Bristol Myers Squibb has made significant strides in the US Glioblastoma Multiforme Market through strategic initiatives that emphasize innovation and access to therapies. The company boasts a strong portfolio that includes key products aimed at tackling various stages of glioblastoma, showcasing its commitment to improving clinical outcomes. Bristol Myers Squibb’s strengths include its solid pipeline, characterized by ongoing clinical trials that explore novel therapies, which could eventually transform patient care. The company has actively pursued mergers and acquisitions to enhance its research capabilities and broaden its therapeutic offerings. This strategic positioning allows Bristol Myers Squibb to maintain a competitive advantage and capitalize on emerging opportunities within the US market. Their focus on targeted therapies and immuno-oncology also reflects a growing trend towards personalized patient care, further solidifying their presence in this challenging market. ### **Key Companies in the US Glioblastoma Multiforme Market Include** - Genentech - Bristol Myers Squibb - Novartis - Celgene - Merck - Eli Lilly - Seattle Genetics - Incyte - Altimmune - Ipsen - Amgen - Roche - [AbbVie](https://news.abbvie.com/2014-08-04-AbbVie-Receives-EMA-and-FDA-Orphan-Drug-Designation-for-Investigational-Compound-ABT-414-in-the-Treatment-of-Glioblastoma-Multiforme) - Alder BioPharmaceuticals - Bayer ## **US Glioblastoma Multiforme Market Industry Developments** Recent developments in the US Glioblastoma Multiforme Market have been characterized by significant advances and corporate movements. In August 2023, Bristol Myers Squibb announced promising results from its clinical trials for the use of nivolumab in combination with other therapies, anticipating a strong impact on treatment landscapes for glioblastoma patients. Meanwhile, Genentech reported updates regarding their ongoing Research and Development efforts related to personalized treatment approaches for brain tumors, indicating a potential shift in patient management strategies. Growth in market valuation has also been observed as investors show increasing confidence in the efficacy of innovative treatment solutions, particularly from companies such as Novartis and Merck. Noteworthy mergers and acquisitions include the acquisition of Celgene by Bristol Myers Squibb, which was finalized in January 2020, consolidating efforts towards glioblastoma research. Furthermore, in December 2022, Roche enhanced its portfolio through the acquisition of a biopharmaceutical firm specializing in immune-oncology treatments, which promises synergistic benefits for glioblastoma therapies. Overall, the evolving landscape holds the potential for expanded treatment options for patients, driven by advancements in technology and collaboration within the sector. ##   ## **Glioblastoma Multiforme Market Segmentation Insights** ### **Glioblastoma Multiforme Market Treatment Type Outlook** - Surgery - Radiation Therapy - Chemotherapy - Immunotherapy - Tumor Treating Field (TTF) Therapy - Others ### **Glioblastoma Multiforme Market End User Outlook** - Hospitals & Clinics - Ambulatory Surgical Centers - Others ## Market Drivers ### Aging Population The aging population in the United States is another significant driver impacting the glioblastoma multiforme market. As individuals age, the risk of developing various types of cancer, including glioblastoma, increases. Current demographic trends indicate that by 2030, approximately 20% of the U.S. population will be aged 65 and older. This demographic shift is likely to result in a higher incidence of glioblastoma, thereby increasing the demand for effective treatment options. Healthcare providers will need to adapt to the growing needs of this aging population, which may lead to an expansion of services and therapies available in the glioblastoma multiforme market. Consequently, the intersection of an aging population and rising cancer incidence presents a compelling opportunity for market growth. ### Rising Incidence Rates The glioblastoma multiforme market is experiencing growth due to the increasing incidence rates of this aggressive brain tumor. In the United States, the annual incidence of glioblastoma is approximately 3.19 cases per 100,000 individuals, which translates to around 13,000 new cases each year. This rising trend in diagnosis is likely to drive demand for innovative treatment options and therapies. As more patients are diagnosed, the healthcare system faces the challenge of providing effective care, thereby creating opportunities for pharmaceutical companies to develop and market new therapies. The increasing patient population is expected to contribute to the expansion of the glioblastoma multiforme market, as healthcare providers seek to address the unmet needs of these patients. ### Growing Awareness and Advocacy Growing awareness and advocacy for glioblastoma multiforme is emerging as a crucial driver in the market. Increased public and professional awareness about the disease is leading to more timely diagnoses and treatment interventions. Advocacy groups are actively working to educate the public and healthcare professionals about glioblastoma, which may result in heightened demand for specialized care and innovative therapies. Additionally, fundraising efforts and awareness campaigns are generating financial support for research initiatives, further propelling advancements in treatment options. As awareness continues to grow, the glioblastoma multiforme market is likely to benefit from increased patient engagement and a stronger push for effective solutions. ### Investment in Research and Development Investment in research and development (R&D) is a critical driver for the glioblastoma multiforme market. Pharmaceutical companies and research institutions are allocating substantial resources to discover novel treatment modalities. In recent years, R&D spending in oncology has surged, with estimates suggesting that it could reach $100 billion annually by 2025. This influx of funding is likely to accelerate the development of targeted therapies and immunotherapies, which may improve patient outcomes. Furthermore, collaborations between academia and industry are fostering innovation, leading to the emergence of new clinical trials and treatment options. As R&D efforts intensify, the glioblastoma multiforme market is poised for significant advancements, potentially transforming the landscape of treatment. ### Regulatory Support for Innovative Therapies Regulatory support for innovative therapies is playing a pivotal role in shaping the glioblastoma multiforme market. The U.S. Food and Drug Administration (FDA) has implemented various initiatives to expedite the approval process for breakthrough therapies, particularly in oncology. Programs such as the Breakthrough Therapy Designation and Accelerated Approval pathway are designed to facilitate faster access to promising treatments for patients with serious conditions. This regulatory environment encourages pharmaceutical companies to invest in the development of novel therapies for glioblastoma, potentially leading to a more diverse range of treatment options. As regulatory frameworks continue to evolve, the glioblastoma multiforme market may witness an influx of innovative therapies that could significantly improve patient outcomes. ## Future Outlook The [Glioblastoma Multiforme Market](https://www.marketresearchfuture.com/reports/glioblastoma-multiforme-market-12161) is projected to grow at 8.52% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness. **New opportunities:** - Development of personalized medicine solutions for glioblastoma patients. Expansion of telehealth services for remote patient monitoring. Investment in innovative drug delivery systems to enhance treatment efficacy. By 2035, the glioblastoma multiforme market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Treatment Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing) The US glioblastoma multiforme market exhibits diverse treatment options with Surgery leading the way in market share. It commands a significant portion due to its critical role in removing tumors and improving patient outcomes. Following closely are Radiation Therapy and Chemotherapy, which remain essential components in comprehensive treatment protocols. Meanwhile, Immunotherapy is gaining traction as a game-changer, particularly in advanced stages, appealing to a growing segment of patients seeking innovative care. Growth trends in the treatment type segment are being driven by advancements in medical technologies and a rising focus on personalized medicine. Immunotherapy is quickly emerging as the fastest-growing treatment option, benefiting from increasing investments and research initiatives. Other therapeutic approaches, such as Tumor Treating Field (TTF) Therapy, are also experiencing expansion as clinical data continues to support their effectiveness, indicating a shifting landscape in treatment methodologies for this aggressive cancer. Surgery: Dominant vs. Immunotherapy: Emerging Surgery remains a dominant treatment approach in the US glioblastoma multiforme market, primarily due to its efficacy in tumor reduction and symptom relief. It is often complemented by adjuvant therapies, such as [Radiation](../../../reports/medical-radiation-shielding-market-24461) Therapy and Chemotherapy, to enhance overall treatment effectiveness. In contrast, Immunotherapy is an emerging therapy garnering attention for its innovative mechanism that helps strengthen the immune response against tumors. This method not only offers new hope for patients but also aligns with current healthcare trends emphasizing personalized treatment plans. As clinical trials continue to unveil promising results, Immunotherapy's market presence is expected to grow significantly, potentially transforming the standard of care in this challenging therapeutic area. ### By End User Type: Hospitals & Clinics (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the US glioblastoma multiforme market, Hospitals & Clinics dominate the end user segment, accounting for the majority of market share. This segment benefits from established infrastructure, comprehensive treatment capabilities, and access to advanced medical technologies. In contrast, Ambulatory Surgical Centers, although smaller in share, are rapidly gaining traction due to their convenience and cost-effectiveness, appealing to a segment of the patient population that prefers less invasive procedures. Growth trends in this segment indicate a shift towards outpatient care, with Ambulatory Surgical Centers projected to expand their footprint. Factors driving this growth include advances in minimally invasive surgical techniques, increased patient preference for outpatient procedures, and the overall focus on reducing healthcare costs. This reflects a transformative approach in the market that emphasizes efficiency and accessibility for glioblastoma treatment. Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals & Clinics serve as the cornerstone of treatment for glioblastoma, providing extensive resources and expertise. They typically offer comprehensive care including surgery, chemotherapy, and radiation therapy, supported by multidisciplinary teams. Their extensive networks and collaborations with research institutions also enhance patient access to clinical trials and new treatments, reinforcing their dominant position in the market. On the other hand, Ambulatory Surgical Centers are emerging as significant players, specializing in less complex procedures and post-operative care for glioblastoma patients. These centers provide an efficient, patient-friendly environment and are ideal for those seeking quick recovery without the need for traditional hospital stays, making them increasingly popular among both patients and payers. ## Competitive Benchmarking The glioblastoma multiforme market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on personalized medicine. Key players such as Bristol-Myers Squibb (US), Merck & Co (US), and Roche (CH) are actively engaged in developing novel therapies and treatment modalities. Bristol-Myers Squibb (US) has positioned itself as a leader in immunotherapy, leveraging its expertise in checkpoint inhibitors to explore combination therapies for glioblastoma. Meanwhile, Merck & Co (US) continues to invest heavily in research and development, focusing on the integration of biomarker-driven approaches to enhance treatment efficacy. Roche (CH) is also making strides in the market, emphasizing its commitment to precision medicine through targeted therapies that address specific genetic mutations associated with glioblastoma. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and patient-centric approaches are paramount. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This collective influence of key players fosters a competitive atmosphere that encourages continuous improvement and adaptation to emerging trends. In October 2025, Bristol-Myers Squibb (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel immunotherapy specifically targeting glioblastoma. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available to patients, reflecting the company's commitment to innovation in oncology. The strategic importance of this partnership lies in its potential to combine resources and expertise, thereby increasing the likelihood of successful clinical outcomes. In September 2025, Merck & Co (US) launched a new clinical trial aimed at evaluating the efficacy of its latest PD-1 inhibitor in combination with chemotherapy for glioblastoma patients. This initiative underscores the company's focus on biomarker-driven therapies, which may lead to more personalized treatment regimens. The trial's outcomes could significantly influence treatment protocols and establish Merck as a frontrunner in the glioblastoma space. In August 2025, Roche (CH) received FDA approval for a new targeted therapy designed to treat glioblastoma patients with specific genetic mutations. This approval not only enhances Roche's product portfolio but also reinforces its strategy of precision medicine. The introduction of this therapy is likely to reshape treatment paradigms and improve patient outcomes, further solidifying Roche's competitive position in the market. As of November 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to tackle complex challenges in glioblastoma treatment. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment. ## Recent News & Developments Recent developments in the US Glioblastoma Multiforme Market have been characterized by significant advances and corporate movements. In August 2023, Bristol Myers Squibb announced promising results from its clinical trials for the use of nivolumab in combination with other therapies, anticipating a strong impact on treatment landscapes for glioblastoma patients. Meanwhile, Genentech reported updates regarding their ongoing Research and Development efforts related to personalized treatment approaches for brain tumors, indicating a potential shift in patient management strategies. Growth in market valuation has also been observed as investors show increasing confidence in the efficacy of innovative treatment solutions, particularly from companies such as Novartis and Merck. Noteworthy mergers and acquisitions include the acquisition of Celgene by Bristol Myers Squibb, which was finalized in January 2020, consolidating efforts towards glioblastoma research. Furthermore, in December 2022, Roche enhanced its portfolio through the acquisition of a biopharmaceutical firm specializing in immune-oncology treatments, which promises synergistic benefits for glioblastoma therapies. Overall, the evolving landscape holds the potential for expanded treatment options for patients, driven by advancements in technology and collaboration within the sector. ##   ## Report Scope | MARKET SIZE 2024 | 617.6(USD Million) | | --- | --- | | MARKET SIZE 2025 | 670.22(USD Million) | | MARKET SIZE 2035 | 1518.46(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.52% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bristol-Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE) | | Segments Covered | Treatment Type, End User Type | | Key Market Opportunities | Advancements in targeted therapies and immunotherapies present growth opportunities in the glioblastoma multiforme market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the glioblastoma multiforme market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of glioblastoma multiforme in 2024?** A: The market valuation of glioblastoma multiforme was $617.6 Million in 2024. **Q: What is the projected market valuation for glioblastoma multiforme by 2035?** A: The projected market valuation for glioblastoma multiforme is $1518.46 Million by 2035. **Q: What is the expected CAGR for the glioblastoma multiforme market during the forecast period 2025 - 2035?** A: The expected CAGR for the glioblastoma multiforme market during the forecast period 2025 - 2035 is 8.52%. **Q: Which treatment type had the highest valuation in the glioblastoma multiforme market in 2024?** A: Chemotherapy had the highest valuation in the glioblastoma multiforme market at $185.76 Million in 2024. **Q: What is the projected valuation for surgery in the glioblastoma multiforme market by 2035?** A: The projected valuation for surgery in the glioblastoma multiforme market is $300.0 Million by 2035. **Q: Which end user type is expected to dominate the glioblastoma multiforme market by 2035?** A: Hospitals & Clinics are expected to dominate the glioblastoma multiforme market with a projected valuation of $850.0 Million by 2035. **Q: What role do key players like Bristol-Myers Squibb and Merck & Co play in the glioblastoma multiforme market?** A: Key players such as Bristol-Myers Squibb and Merck & Co are instrumental in driving innovation and competition within the glioblastoma multiforme market. **Q: How does the valuation of immunotherapy compare to other treatment types in 2024?** A: In 2024, immunotherapy was valued at $92.88 Million, which is comparable to radiation therapy at $92.88 Million. **Q: What is the projected growth for tumor treating field (TTF) therapy by 2035?** A: The projected growth for tumor treating field (TTF) therapy is expected to reach $150.0 Million by 2035. **Q: What is the significance of the 'Others' segment in the glioblastoma multiforme market?** A: The 'Others' segment, valued at $61.92 Million in 2024, indicates a diverse range of treatment options that may gain traction in the future. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-glioblastoma-multiforme-market-13698*